BION­CaRT GmbH emerged from Bio­Planta GmbH, which has been devel­op­ing and man­u­fac­tur­ing cell ther­apy prod­ucts from mes­enchy­mal stro­mal cells for clin­i­cal appli­ca­tion in humans and con­duct­ing pre­clin­i­cal stud­ies for sev­eral years. As a research-based phar­ma­ceu­ti­cal com­pany, BION­CaRT is involved in the trans­la­tion of bio­med­ical drugs for clin­i­cal appli­ca­tion in humans, in par­tic­u­lar for the treat­ment of orthopaedic dis­eases. The focus here is on allo­geneic ther­apy con­cepts (use of cells from other patients).